Nintedanib (Ofev) prior authorization at Florida Blue
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Florida Blue requires prior-authorization documentation for Nintedanib (Ofev): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Florida Blue reviews Nintedanib (Ofev) prior authorizations against its medical policy . Florida Blue-specific context: BCBS licensee for Florida (~5M members). Owned by GuideWell. Prime Therapeutics is the PBM (BCBS-aggregated PBM serving 19 BCBS plans). Florida OIR oversight. Largest ACA Marketplace participant in FL.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Florida Blue's medical policy URL referenced in the cover letter
Florida Blue's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace narrow-network denials (BlueCare, myBlue)
- Step therapy via Prime Therapeutics PBM
- Out-of-network reductions citing UCR
- Specialty drug prior auth
Nintedanib (Ofev)-specific denial patterns and context
Across payers (not just Florida Blue), Nintedanib (Ofev)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- FVC threshold requirements
- Indication restriction (IPF vs SSc-ILD vs PPF)
- GI tolerability not adequately documented
- LFT monitoring not documented
Brand: Ofev. Tyrosine kinase inhibitor (antifibrotic). FDA-approved for IPF, SSc-ILD (2019), and chronic fibrosing ILDs with progressive phenotype (PPF, 2020) — broader label than pirfenidone.
Manufacturer patient-assistance program: OFEV BI Cares Foundation — relevant when a Florida Blue denial sticks and the patient needs bridge access while appealing.
How Florida Blue approaches Antifibrotic agents PAs
Florida Blue's Antifibrotic agents reviewer typically anchors Nintedanib prior-auth decisions on step therapy via prime therapeutics pbm and specialty drug prior auth. Pharmacy-benefit review for Nintedanib at Florida Blue is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Florida Blue's FVC-threshold restrictions are increasingly out of step with ATS/ERS/JRS/ALAT 2022 guidance, which recommends antifibrotic initiation regardless of FVC band. Florida Blue is domiciled in FL, so unresolved appeals escalate to the FL insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for Florida (~5M members).
If the PA is denied
Florida Blue gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.floridablue.com) with the same packet plus a peer-reviewed citation supporting Nintedanib (Ofev)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Florida Blue denial on DenialHelp.
Contact Florida Blue
- Provider portal: https://providers.floridablue.com
Frequently asked questions
What documentation does Florida Blue need for Nintedanib (Ofev) prior auth?
Florida Blue's typical PA packet for Nintedanib (Ofev): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Florida Blue?
Standard Nintedanib (Ofev) PA decisions at Florida Blue: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Florida Blue most often reject Nintedanib (Ofev) for?
Across Florida Blue's book the common rejection patterns include: Marketplace narrow-network denials (BlueCare, myBlue); Step therapy via Prime Therapeutics PBM; Out-of-network reductions citing UCR. For Nintedanib (Ofev) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Does Florida Blue's FVC threshold for Nintedanib match current ATS guidance?
Many Florida Blue antifibrotic policies require FVC 50-80% predicted, but the 2022 ATS/ERS/JRS/ALAT IPF guideline recommends antifibrotic initiation regardless of FVC band — citing this guidance in appeals frequently overturns FVC-threshold denials. Attach the HRCT report with UIP or probable-UIP pattern, multidisciplinary discussion documentation, and the specific FVC value with rate of decline if available. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Florida Blue fully-insured policies sits with the FL insurance department.
How do I prep for a peer-to-peer with Florida Blue on Nintedanib (Ofev)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Nintedanib (Ofev) PA packet
Open ApprovalHelp — generate a Nintedanib (Ofev) prior-auth packet tailored to Florida Blue's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com